Guided Therapeutics Inc (GTHP) Stock Price & Analysis
Guided Therapeutics Inc (GTHP) fell 12.28% to USD 0.2 as of June 10, 2026 at 04:03 UTC, according to Nexqual real-time market data.
GTHP last closed at USD 0.23; the session ranged USD 0.2–0.23 on volume of 6,000 shares. Market capitalization is $19.31M, with a 52-week range of USD 0.12–0.54 (OQB). Source: Nexqual, June 10, 2026 at 04:03 UTC.
Key Statistics (as of June 10, 2026 at 04:03 UTC)
| Price | USD 0.2 |
|---|---|
| Change | ▼ 12.28% (down) |
| Previous Close | USD 0.23 |
| Open | USD 0.23 |
| Day Range | USD 0.2 – 0.23 |
| 52-Week Range | USD 0.12 – 0.54 |
| Volume | 6,000 shares |
| Market Cap | $19.31M |
| Exchange | OQB |
Technical Analysis (GTHP)
Nexqual's technical model rates GTHP "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:03 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 47.17 (neutral) |
| vs SMA50 | Below (USD 0.21) |
| MACD | -0 (negative) |
Analyst Ratings (GTHP)
Wall Street analysts rate GTHP "None", per Nexqual as of June 10, 2026 at 04:03 UTC.
| Consensus Rating | None |
|---|
Earnings (GTHP)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2013-03-31 | USD -1,919,385.8 vs est -640,000 ▼ miss |
| 2012-12-31 | USD -1,279,590.5 vs est -640,000 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:03 UTC.
Financials & Fundamentals (GTHP)
| Total Revenue | $767,000 |
|---|---|
| Gross Margin | +74.45% |
| Operating Margin | -294.65% |
| Profit Margin | +0.00% |
| Current Ratio | 0.15 |
| Total Cash | $369,000 |
| Total Debt | $2.79M |
| Free Cash Flow | $-880,625 |
Source: Nexqual, June 10, 2026 at 04:03 UTC.
Financial Health Score (GTHP)
Nexqual rates Guided Therapeutics Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:03 UTC.
| Growth | Strong — Revenue +39% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $369K cash vs $3M debt |
| Cash Flow | Weak — FCF negative: -$881K, burning cash |
| Efficiency | Mixed — No data |
Ownership (GTHP)
| Insider Ownership | +36.52% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 96.54M |
| Float | 40.10M |
Source: Nexqual, June 10, 2026 at 04:03 UTC.
Leadership (GTHP)
Guided Therapeutics Inc is led by Mark L. Faupel (age 70), CEO, President, COO, Acting CFO, Secretary & Director, per Nexqual as of June 10, 2026 at 04:03 UTC.
| CEO, President, COO, Acting CFO, Secretary & Director | Mark L. Faupel (age 70) |
|---|
From Guided Therapeutics Inc's Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Guided Therapeutics, Inc., a medical technology company, researches, develops, tests, manufactures, sells, and distributes medical devices in the United States and internationally.
- It offers LuViva, an advanced cervical scan non-invasive cervical cancer detection device that provides less invasive and painless alternative to conventional tests for identifying, screening, and detecting cervical cancers and precancers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BICX | BioCorRx Inc. | USD 0.4 | ▲ 5.82% |
| RGRX | REGENERX BIOPHARMACEUTICALS | USD 0 | ▲ 0% |
| NEPH | Nephros, Inc. | USD 3.25 | ▼ 4.97% |
| AMBS | Amarantus Bioscience Holdings, | USD 0 | ▲ 0% |
| LLBO | Lifeline BioTechnologies, Inc. | USD 0 | ▲ 40% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:03 UTC. This page is informational and not investment advice.